[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591638":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":29,"centralContacts":34,"locations":40,"responsibleParty":58,"collaborators":28,"id":60,"slug":28,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":28,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":28,"enrollmentInfo":68,"targetDuration":28,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":80,"overallStatus":42,"whyStopped":28,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Vera Therapeutics, Inc.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"IgAN or IgAVN","EXPERIMENTAL","Adult and pediatric patients with biopsy proven IgAN or IgAVN with varied severity of proteinuria and kidney function beyond what is currently included in most clinical trials. Adults with post-transplant IgAN recurrence are also included.",[13],"Drug: Atacicept",{"label":15,"type":10,"description":16,"interventionNames":17},"pMN","Adults with biopsy-proven pMN associated with anti-PLA2R antibodies at low risk of spontaneous remission, or experiencing recurrent or resistant disease.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Primary Nephrotic Syndrome (MCD\u002FFSGS)","Adults with biopsy-proven primary MCD or FSGS and evidence of anti-nephrin antibodies. Children with frequently relapsing, steroid-dependent, or non-genetic steroid-resistant nephrotic syndrome with evidence of anti-nephrin antibodies.",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Atacicept","Atacicept 150 mg SC QW via pre-filled syringe",[9,19,15],null,[30],{"name":31,"affiliation":32,"role":33},"Pam Winterberg","Vera Therapeutics","STUDY_DIRECTOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":28,"email":39},"Vera Therapeutics, Inc. Clinical Trials Information","CONTACT","650-770-0077","PIONEERStudy@veratx.com",[41],{"facility":32,"status":42,"city":43,"state":44,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Brisbane","California","94005","United States",{"type":48,"coordinates":49},"Point",[50,51],-122.39997,37.68077,{"lat":51,"lon":50},[54],{"name":55,"role":37,"phone":56,"phoneExt":28,"email":57},"Brisbane, California","(650)770-0077","clinicaltrials@veratx.com",{"type":59,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100591638",false,"NCT06983028","Atacicept in Multiple Glomerular Diseases","A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)","Inclusion Criteria:\n\n* Weight of at least 40 kg\n* On a stable prescribed standard of care (SoC) treatment regimen according to local guidelines and the specific requirements for each disease\n* Systolic blood pressure ≤160 mmHg and diastolic blood pressure ≤90 mmHg at Screening.\n\nDiagnosis of IgAN, IgAVN, pMN, MCD, FSGS, or primary nephrotic syndrome\n\nFor patients enrolling in IgAN cohorts (eligibility varies by cohort):\n\n* Age ≥ 18 years\n* Biopsy proven IgAN, IgAVN, or recurrent IgAN in kidney transplant\n* UPCR ≥ 0.5 g\u002Fg or UPE ≥ 0.5 g\u002Fday on 24h urine\n* eGFR≥ 20 mL\u002Fmin\u002F1.73m2\n\nFor patients enrolling in pediatric IgAN Cohorts (eligibility varies by cohort):\n\n* Age ≥ 2 years and \\\u003C 18 years\n* Biopsy proven IgAN or IgAVN\n* On stable prescribed regimen of RAASi (or SoC) for at least 8 weeks\n* UPCR ≥ 1.0 g\u002Fg or UPE ≥ 1.0 g\u002Fd on 24h urine\n* eGFR≥ 30 mL\u002Fmin\u002F1.73m2\n\nFor patients enrolling in pMN cohorts (eligibility varies by cohort):\n\n* Age ≥ 18 years\n* Biopsy-proven pMN\n* Anti PLA2R antibodies ≥ 25 RU\u002FmL\n* UPCR ≥ 1.5 g\u002Fg or UPE ≥ 1.5 g\u002Fd on 24h urine\n* At low risk for spontaneous remission (based on severity or duration of disease)\n\nFor patients enrolling in Nephrotic Syndrome cohorts (MCD, FSGS, or pediatric idiopathic nephrotic syndrome):\n\n* Age ≥ 10 years\n* eGFR ≥30 mL\u002Fmin\u002F1.73m2\n* Adults with biopsy diagnosis of primary MCD or FSGS (adults) or children with challenging clinical course with steroids (frequenlty relapsing, steroid-dependent, or steroid-resistant)\n* UPCR ≥ 1.0 g\u002Fg or UPE ≥ 1.0 g\u002Fd on 24h urine\n* Evidence of anti-nephrin antibodies\n\nKey Exclusion Criteria:\n\n* Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR) within 12 weeks prior to and at Screening)\n* Active viral or bacterial infections\n* Existing conditions or clinically significant laboratory abnormalities that may interfere with participation in this study\n* Administration of live and live-attenuated vaccinations within 30 days prior to enrollment\n* Immunosuppressant medications within 4 weeks prior to dosing with atacicept (except transplant maintenance immunosuppression).\n* Known hypersensitivity to atacicept or any component of the formulated atacicept\n* Additional criteria apply to each cohort\u002Fdisease.","ALL","2 Years",{"count":69,"type":70},250,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.",[15,76,77,78,79],"IgAN","Nephrotic Syndrome","MCD","FSGS",[81,82,83,84,85,86,77,87,88,89,90,91,92,93,94,95,96],"IGA Glomerulonephritis","IGA Nephropathy","Iga Nephropathy 1","Immunoglobulin A Nephropathy Nephritis","IGA Type Nephropathy, IGA","Primary Membranous Nephropathy","Immunoglobulin A (IgA)","Immunoglobulin A vasculitis with nephritis (IgAVN)","Anti-PLA2R associated membranous nephropathy (PLA2R-MN)","Idiopathic\u002Fprimary nephrotic syndrome (MCD\u002FFSGS)","Glomerulonephritis","Nephritis","Autoimmune Diseases","Immune System Diseases","Kidney Diseases","Glomerulonephritis, IGA","2026-06-23",{"date":99,"type":100},"2026-06-26","ACTUAL",{"date":102,"type":100},"2025-07-07",{"date":104,"type":70},"2027-11",{"name":5,"class":6},1]